With the stock now trading well above $150, investors are debating how much further PRAX could rise. If ulixacaltamide wins approval, analysts believe it could capture a sizable ET market. However, success in neurology trials can be binary – failures or setbacks could send the stock sharply down. Looking ahead, Praxis expects more data by late 2025/early 2026. Management’s guidance has focused on these milestones rather than concrete revenue forecasts, which is typical for clinical-stage biotechsnasdaq.com. In the near term, analysts will scrutinize FDA feedback and the actual content of the trial data. As Reuters summarized, the Phase 3 win “gives hope” for a much-needed new ET therapyreuters.com. Coupled with a healthy cash position and ongoing epilepsy trials, many experts now view Praxis’s prospects more favorably. Still, they caution that valuation is stretched – PRAX’s market cap reflects sky-high expectations that all these programs succeed. As of Oct. 16, 2025, the stock is riding a wave of bullish sentiment, but investors will want hard evidence from regulators and future studies before declaring victoryreuters.comneurologylive.com.
